MSH2 and neoplasm: We performed targeted testing of DNA from the adjacent normal colorectal mucosa (NCM) and tumor tissues to determine carrier status of the MSH2 and MSH6 variants and seek loss-of-heterozygosity (LOH) as a potential “second hit” in tumorigenesis.